Pharma & Biotech Intelligence

Spot the signals.

Clinical trial surveillance, patent intelligence, and biomarker strategy — built from public FDA and ClinicalTrials.gov data.

0+
trial protocols benchmarked
0
ADC oncology targets mapped
0
patent-cliff candidates
0
intelligence modules
✓ FDA Orange Book✓ ClinicalTrials.gov✓ Updated monthly
Clinical SurveillanceLive

Clinical Program Risk Radar

Track public delay, termination, recruitment burden, and missing-results signals across oncology Phase 2 assets.

Lumicras
NSCLC · Mirati Therapeutics
Registry Stop
Cellara
ovarian cancer · Cellara Therapeutics
Registry Stop
CLDNova
gastric cancer · Claudia Bio
Timeline Staleness
ClinicalTrials.govRegistry snapshots
Patent IntelligenceLive

Generic Entry Radar

Screen U.S. small-molecule drugs for near-term loss-of-exclusivity windows, scored by expiry attractiveness and patent complexity.

FDA Orange BookClinicalTrials.gov
Clinical + PatentLive

ADC Target Strategy Radar

Map oncology ADC targets by clinical crowding, sponsor competition, patent-density signals, and strategic labels.

ClinicalTrials.govPatent signals
Translational BDLive

Translational Deal Radar

Screen translational programs for clinical momentum, IP-linkage signals, and BD relevance before deeper diligence begins.

ClinicalTrials.govPatent signals
Trial DesignLive

Protocol Benchmark Radar

Benchmark public trial designs by endpoint precedent, eligibility burden, biomarker strategy, and operational risk.

ClinicalTrials.govRegistry text
Precision OncologyLive

Biomarker Patient-Selection Radar

Track how oncology biomarkers are used for patient selection, with FDA CDx context and diagnostic patent-density signals.

ClinicalTrials.govFDA CDx data

Structured outputs

Public biomedical databases are searchable, but search is not intelligence. Treelip transforms raw records into decision-specific modules with structured outputs, confidence labels, and evidence trails.

Explainable signals

Every signal is source-linked, clearly labelled, and explainable. Conservative interpretation, transparent methodology, and manual-review flags — not black-box claims.

Compounding intelligence

Treelip becomes more valuable as it accumulates historical snapshots, change events, entity mappings, and watchlists. The long-term moat is the curated, versioned intelligence layer.

Pharma / BiotechBusiness DevFinance & InvestorsCROsDiagnosticsGeneric PharmaMarket Intelligence
About Treelip

A practical intelligence layer for pharma strategy

Treelip is an independent platform that builds deterministic, public-data intelligence tools for pharma BD, strategy, and market intelligence teams. Each module is built from public databases — FDA Orange Book, ClinicalTrials.gov, and related public sources — with transparent methodology pages explaining every signal.

Outputs are designed for first-pass prioritisation and expert review support, not automated decisions. Treelip does not replace expert clinical, legal, regulatory, or investment judgment. It helps experts focus their attention faster.

How Treelip is delivered: Public teaser dashboards · Gated CSV downloads · Monthly intelligence briefs · Custom asset or target reports · Watchlist monitoring.

Get Access

Stay ahead of what's moving in pharma

Enter your name and email to register interest. We use this to manage email subscriptions, future CSV delivery, and product access follow-up.

We store name, email, tool selections, CSV delivery preferences, notes, timestamp, source page, and any optional company or request details for internal follow-up. Do not submit confidential or commercially sensitive information through this form.